XML 56 R55.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details 5)
 12 Months Ended 0 Months Ended
Feb. 28, 2015
Mar. 01, 2014
Mar. 02, 2013
Feb. 17, 2014
Derivatives        
Number of interest rate swap arrangements or other derivatives held 0us-gaap_DerivativeNumberOfInstrumentsHeld 0us-gaap_DerivativeNumberOfInstrumentsHeld    
Pharmacy sales | Customers | Top five third party payors        
Significant Concentrations        
Percentage of concentration risk 69.70%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rad_TopFiveThirdPartyPayorsMember		      
Pharmacy sales | Customers | Largest third party payor | Express Scripts        
Significant Concentrations        
Percentage of concentration risk 27.80%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_CounterpartyNameAxis
= rad_ExpressScriptsMember
/ us-gaap_MajorCustomersAxis
= rad_LargestThirdPartyPayorsMember		 31.60%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_CounterpartyNameAxis
= rad_ExpressScriptsMember
/ us-gaap_MajorCustomersAxis
= rad_LargestThirdPartyPayorsMember		 35.30%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_CounterpartyNameAxis
= rad_ExpressScriptsMember
/ us-gaap_MajorCustomersAxis
= rad_LargestThirdPartyPayorsMember		  
Pharmacy sales | Customers | Medicaid agencies and related managed care Medicaid payors        
Significant Concentrations        
Percentage of concentration risk 18.60%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rad_MedicaidAgenciesAndRelatedManagedCareMedicaidPayorsMember		      
Pharmacy sales | Customers | Largest Medicaid agency        
Significant Concentrations        
Percentage of concentration risk 1.30%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rad_LargestMedicaidAgenciesMember		      
Pharmacy sales | Customers | Medicare Part D        
Significant Concentrations        
Percentage of concentration risk 32.10%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesRevenueGoodsNetMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rad_MedicarePartDMember		      
Purchases | Suppliers | McKesson Corp.        
Significant Concentrations        
Percentage of concentration risk 94.80%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_CostOfGoodsTotalMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_SupplierConcentrationRiskMember
/ us-gaap_CounterpartyNameAxis
= rad_McKessonCorporationMember		      
Period for Purchasing and Delivery Arrangement       5 years